 Regimen A: Bevacizumabanastrozole with trastuzumab in HER2 patients. Bevacizumab 10mgkg IV every 2 weeks patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mgkg every 3 weeks instead of 10 mgkg every 2 weeks see Trastuzumab section below and anastrozole 1 mg orally daily. Treatment will be given in 4-week cycles. Response assessments will be performed after 2 cycles. Patients who respond to treatment or have stable disease will continue to be evaluated every 2 cycles. After 6 months, response assessment will occur every 3 months. A patient may remain on study if radiation is deemed necessary and appropriate, provided that there are other sites of measurable disease outside the field of radiation that may be followed. Treatment occurs until disease progression. Patients will be selected for this treatment arm per the following guidelines: 12 months from adjuvant endocrine therapy OR 12 months from adjuvant aromatase inhibitors OR Endocrine therapy naive OR Prior tamoxifen exposure or tamoxifen intolerance 